🔍

JLHL - Jupiter Life Lin

📊 NSE: JLHL 🏢 Healthcare 📅 Last Updated: 12/14/2025 8:43

📢 Recent Corporate Announcements

ICRA Assigns [ICRA]AA- (Stable) Rating to JLHL Subsidiary's Rs 255 Cr Bank Facilities

🟢 POSITIVE ⭐ 7/10

ROUTINE 📅 10 Mar 2026, 05:23 PM

ICRA has assigned credit ratings to the bank facilities of Jupiter Hospital Projects Private Limited, a material subsidiary of Jupiter Life Line Hospitals Limited. A long-term rating of [ICRA]AA- with a stable outlook was assigned to a Rs 250 crore term loan. Additionally, short-term facilities totaling Rs 5 crore were assigned the highest rating of [ICRA]A1+. These ratings indicate a strong credit profile and financial stability for the subsidiary's operations.

ICRA assigned [ICRA]AA- (Stable) rating to a Rs 250 crore long-term term loan.
Short-term fund-based overdraft of Rs 5 crore assigned [ICRA]A1+ rating.
Non-fund based bank guarantee sublimit of Rs 4 crore assigned [ICRA]A1+.
Total bank facilities rated by ICRA for the subsidiary amount to Rs 255 crore.

💡 The high credit ratings reflect the subsidiary's strong debt-servicing capability and the parent's overall financial health. Investors should maintain a positive outlook on the stock given the low credit risk and stable financial position.

Jupiter Life Line Hospitals Schedules Analyst Group Meeting at Dombivli Facility on March 6

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 27 Feb 2026, 07:30 PM

Jupiter Life Line Hospitals Limited (JLHL) has announced a group meeting with analysts and institutional investors scheduled for March 6, 2026. The interaction will occur at the company's Dombivli Hospital facility in Maharashtra from 2:00 PM to 4:30 PM. The company stated that the discussions will focus on publicly available documents and will not involve any unpublished price sensitive information. Such meetings are standard practice for listed entities to engage with the investment community and showcase operational facilities.

Group meeting with analysts and institutional investors scheduled for March 6, 2026.
Interaction includes a site visit to the Dombivli Hospital facility in Maharashtra.
Meeting duration is set for 2.5 hours, from 2:00 PM to 4:30 PM.
Disclosure made under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.

💡 This is a routine investor relations event; investors should look for any subsequent corporate presentations that might summarize the discussions or operational updates.

Jupiter Life Line Hospitals to Attend Kotak Investor Conference on Feb 25, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 18 Feb 2026, 12:55 PM

Jupiter Life Line Hospitals Limited (JLHL) has announced its participation in an upcoming investor conference organized by Kotak Institutional Equities. The meeting is scheduled for February 25, 2026, in Mumbai, running from 11:00 am to 05:00 pm. The company management will interact with institutional investors using only publicly available information. Such meetings are standard practice for listed companies to maintain transparency and engage with the investment community.

Investor conference scheduled for February 25, 2026, in Mumbai.
Event organized by Kotak Institutional Equities from 11:00 am to 05:00 pm.
Company officials will participate to discuss performance based on public documents.
No unpublished price sensitive information (UPSI) will be shared during the session.

💡 Investors should watch for any corporate presentations or transcripts that may be uploaded to the exchange following the conference. No immediate trading action is required as this is a routine disclosure.

JLHL to Launch 500-Bed Dombivli Hospital Early; Q3 Revenue Up 9.8% to INR 365.3 Cr

🔵 WATCH ⭐ 8/10

EARNINGS 📅 05 Feb 2026, 05:39 PM

Jupiter Life Line Hospitals (JLHL) reported a 9.8% YoY revenue growth in Q3 FY26 to INR 365.3 Cr, though PAT declined 18.7% to INR 42.5 Cr due to a one-time INR 6.4 Cr labor code provision. The company announced the early completion of its 500-bed Dombivli facility at a capex of INR 425 Cr, with operations starting in February 2026. Management cautioned that the new facility will cause an EBITDA drag and higher depreciation for approximately two years during its stabilization phase. Operational metrics for 9M FY26 remain stable with an ARPOB of INR 66,800 and 61.9% occupancy.

Dombivli hospital (500 beds) completed ahead of schedule in 24 months at a capex of INR 425 Cr.
Q3 FY26 Revenue grew 9.8% YoY to INR 365.3 Cr, while EBITDA margins remained steady at 22.8%.
PAT impacted by a one-time exceptional provision of INR 6.4 Cr related to the new Labor Code.
9M FY26 ARPOB stood at INR 66,800 with an average occupancy of 61.9%.
Management expects the new Dombivli facility to reach EBITDA breakeven by the end of its second year.

💡 Investors should focus on the occupancy ramp-up at the Dombivli facility, as initial operating losses and high depreciation will likely pressure consolidated margins for the next 1-2 years. The early project execution is a positive indicator of management capability, but short-term earnings may remain muted.

Jupiter Life Line Hospitals to Attend Nuvama Investor Conference on February 10, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 04 Feb 2026, 01:59 PM

Jupiter Life Line Hospitals Limited (JLHL) has scheduled meetings with institutional investors and analysts on February 10, 2026, in Mumbai. The interactions will take place between 2:00 pm and 5:00 pm as part of the Nuvama Conference. The company will engage in both 1x1 and group meeting formats to discuss publicly available information. Management has clarified that no unpublished price sensitive information (UPSI) will be shared during these sessions.

Meeting scheduled for February 10, 2026, from 2:00 pm to 5:00 pm
Participation in the Nuvama Conference held in Mumbai
Format includes both 1x1 and group interactions with institutional investors
Company confirms no unpublished price sensitive information (UPSI) will be disclosed

💡 This is a routine regulatory disclosure; investors should monitor for any subsequent investor presentations or transcripts that may provide insights into the company's operational outlook.

Jupiter Life Line Hospitals Releases Q3 & 9M FY26 Earnings Call Audio Recording

🟡 NEUTRAL ⭐ 4/10

EARNINGS 📅 02 Feb 2026, 01:24 PM

Jupiter Life Line Hospitals Limited has officially released the audio recording of its investor conference call held on February 2, 2026. The call focused on the financial and operational performance for the third quarter and the nine-month period ending December 31, 2025. This disclosure is in compliance with SEBI Listing Obligations and Disclosure Requirements. Investors can now access the management's detailed commentary and responses to analyst queries via the company's website.

Audio recording for Q3 and 9M FY26 earnings call is now available for public access
The conference call was conducted on February 2, 2026, at 10:00 A.M. IST
Disclosure made under Regulation 30 and 46(2) of SEBI LODR Regulations
Recording covers performance updates for the period ending December 31, 2025

💡 Investors should listen to the recording to understand management's guidance on bed occupancy and expansion plans. This is a routine but essential step for a thorough fundamental analysis of the company's quarterly performance.

Jupiter Life Line Q3 Income Up 9.8% to ₹365Cr; Dombivli Hospital Finished Ahead of Schedule

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 31 Jan 2026, 02:03 PM

Jupiter Life Line Hospitals (JLHL) reported a 9.8% YoY growth in total income to ₹365.3 crore for Q3FY26, with a revised EBITDA of ₹85.4 crore. A major strategic milestone was achieved with the completion of the 500-bed Dombivli hospital in just 24 months, ahead of its Q1FY27 target. However, PAT for the quarter declined 18.7% YoY to ₹42.5 crore, largely due to a ₹6.4 crore statutory impact from New Labour Code changes and higher depreciation. Operational metrics remain robust, with ARPOB increasing to ₹66,800, although occupancy moderated to 61.9% due to capacity expansion.

Dombivli hospital (500-bed capacity) completed ahead of schedule with Phase I operations starting Feb 2026.
9MFY26 Total Income rose 15.1% YoY to ₹1,111.9 crore, while EBITDA grew 15.2% to ₹249.2 crore.
Average Revenue Per Occupied Bed (ARPOB) grew significantly to ₹66,800 in 9MFY26 from ₹59,000 in 9MFY25.
Q3FY26 PAT of ₹42.5 crore was impacted by a ₹6.4 crore exceptional item related to New Labour Code changes.
Total bed capacity is projected to reach ~2,500 beds with upcoming projects in Pune and Mira-Bhayandar.

💡 Investors should focus on the long-term growth potential unlocked by the early operationalization of the Dombivli facility. While short-term margins were hit by regulatory costs, the strong ARPOB growth and aggressive capacity expansion plan justify a positive outlook.

Jupiter Life Line Q3 Revenue Up 10%; Dombivli Hospital Completed Ahead of Schedule

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 30 Jan 2026, 05:29 PM

Jupiter Life Line Hospitals reported a 9.8% YoY growth in total income for Q3FY26 at Rs 365.3 crore, while 9MFY26 income rose 15.1% to Rs 1,111.9 crore. The company successfully completed its 500-bed Dombivli hospital ahead of schedule, with Phase I (200 beds) set for full clinical operations by February 18, 2026. Despite revenue growth, Q3 PAT declined 18.7% YoY to Rs 42.5 crore, primarily due to a Rs 6.4 crore impact from New Labour Code changes and higher depreciation. Operating metrics remain strong with ARPOB increasing to Rs 66,800 in 9MFY26 compared to Rs 59,000 in the previous year.

9MFY26 Total Income grew 15.1% YoY to Rs 1,111.9 crore with EBITDA rising 15.2% to Rs 254 crore.
Dombivli hospital (500-bed capacity) completed in 24 months, ahead of the Q1FY27 target, with Rs 425 crore capex incurred.
Average Revenue Per Occupied Bed (ARPOB) improved significantly to Rs 66,800 in 9MFY26 from Rs 59,000 in 9MFY25.
Company plans to expand total capacity to ~2,500 beds by adding ~1,452 beds across Dombivli, Pune, and Mira-Bhayandar.
Q3 PAT was impacted by a one-time statutory charge of Rs 6.4 crore related to New Labour Code changes.

💡 Investors should view the early operationalization of the Dombivli facility as a significant growth catalyst for FY27. Monitor the occupancy ramp-up at the new facility and the management's ability to maintain high ARPOB levels amidst capacity expansion.

Jupiter Life Line Hospitals to Start 200-Bed Dombivli Facility on Feb 15, 2026

🟢 POSITIVE ⭐ 8/10

EXPANSION 📅 30 Jan 2026, 05:23 PM

Jupiter Life Line Hospitals (JLHL) has announced the successful completion and commencement of operations at its new quaternary care hospital in Dombivli, Mumbai Metropolitan Region. The facility, which has a total planned capacity of 500 beds, will initially open with 200 operational beds following its inauguration on February 15, 2026. This project was a key milestone outlined in the company's 2023 IPO prospectus. The timely execution and licensing of this large-scale facility are expected to drive significant revenue growth in the coming fiscal years.

New 500-bed quaternary care hospital completed in Dombivli, Mumbai Metropolitan Region
Initial phase of 200 beds to become operational starting February 15, 2026
All major requisite licenses for the facility have been successfully obtained
Expansion aligns with the long-term growth strategy disclosed in the September 2023 prospectus

💡 Investors should track the occupancy ramp-up and contribution to margins from this new facility over the next 2-4 quarters. The expansion significantly increases the company's total bed capacity and strengthens its presence in the high-demand Mumbai market.

Jupiter Life Line Hospitals Q3 PAT Dips 9.8% YoY to ₹44.3 Cr; Revenue Up 7.8%

🟡 NEUTRAL ⭐ 8/10

EARNINGS 📅 30 Jan 2026, 04:54 PM

Jupiter Life Line Hospitals reported a standalone revenue of ₹291.4 crore for Q3 FY26, marking a 7.8% growth compared to the same quarter last year. However, Profit After Tax (PAT) declined by 9.8% YoY to ₹44.3 crore, largely due to a one-time exceptional charge of ₹5.54 crore related to the implementation of New Labour Codes. On a sequential basis, the company saw a decline in both revenue and profit compared to Q2 FY26. For the nine-month period ended December 2025, the company maintained a stable PAT of ₹142.2 crore.

Standalone Revenue from Operations grew 7.8% YoY to ₹2,913.98 million.
Standalone PAT decreased to ₹442.79 million from ₹491.07 million in Q3 FY25.
Recorded an exceptional expense of ₹55.44 million due to increased gratuity liability under New Labour Codes.
9M FY26 Revenue reached ₹8,852.01 million, a significant increase from ₹6,012.11 million in 9M FY25.
Basic EPS for the quarter stood at ₹6.75, down from ₹7.52 in the corresponding previous year quarter.

💡 Investors should note that the profit dip is partially due to a non-recurring exceptional item; however, the sequential (QoQ) decline in revenue and margins warrants a cautious watch on operational efficiency.

Jupiter Life Line Hospitals to Discuss Q3 & 9M FY26 Results on Feb 2, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 23 Jan 2026, 06:23 PM

Jupiter Life Line Hospitals Limited (JLHL) has scheduled its earnings conference call for Monday, February 2, 2026, at 10:00 AM IST. The management, led by Joint MD and CEO Dr. Ankit Thakker, will discuss the company's operational and financial performance for the third quarter and nine months ended December 31, 2025. Investors can access the call via primary numbers +91 22 6280 1309 or +91 22 7115 8210. This is a standard regulatory disclosure following the conclusion of the December quarter.

Earnings call scheduled for February 2, 2026, at 10:00 AM IST
Discussion to cover Q3 and 9M FY26 operational and financial performance
Management representation by Joint MD and CEO Dr. Ankit Thakker
International toll-free access provided for USA, UK, Singapore, and Hong Kong

💡 Investors should attend the call to understand management's outlook on bed occupancy and expansion plans. No immediate action is required as this is a routine scheduling announcement.

Jupiter Life Line Hospitals Files Q3 FY26 Share Dematerialization Compliance Certificate

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 06 Jan 2026, 05:45 PM

Jupiter Life Line Hospitals Limited has submitted its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations for the period ended December 31, 2025. The certificate, issued by KFin Technologies Limited, confirms that the entire shareholding of the company is held in dematerialized form. No requests for rematerialization of shares were received during the quarter. This filing is a standard administrative requirement for listed companies in India to ensure accurate shareholding records.

Compliance certificate filed for the quarter ended December 31, 2025.
Confirmed that 100% of the company's shares are maintained in dematerialized form.
Zero rematerialization requests were received during the reporting period.
The certificate was verified and issued by Registrar and Share Transfer Agent, KFin Technologies Limited.

💡 This is a routine regulatory filing with no impact on the company's valuation or operations. Investors should focus on the company's upcoming quarterly financial results for material performance updates.

Jupiter Life Line Hospitals to Close Trading Window from January 1, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 24 Dec 2025, 03:37 PM

Jupiter Life Line Hospitals Limited (JLHL) has announced the closure of its trading window for all designated persons and their immediate relatives starting January 1, 2026. This regulatory action is in compliance with SEBI (Prohibition of Insider Trading) Regulations for the upcoming financial results. The closure pertains to the unaudited financial results for the quarter and nine months ending December 31, 2025. The window will remain closed until 48 hours after the results are officially declared to the stock exchanges.

Trading window closure effective from Thursday, January 1, 2026.
Applies to financial results for the quarter and nine months ending December 31, 2025.
Restriction remains in place until 48 hours post-declaration of results.
NSDL designated to freeze PAN at security level for ISIN INE682M01012.
Compliance follows SEBI Circular No. SEBI/HO/ISD/ISD-POD-2/P/CIR/2023/124.

💡 This is a routine regulatory filing ahead of quarterly earnings and requires no immediate action. Investors should monitor for the upcoming board meeting date to assess the company's Q3 performance.

View All JLHL Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Total revenue grew 18.0% in FY2025 to INR 1,261.5 Cr, following a 19.8% growth in FY2024 to INR 1,069.5 Cr. H1 FY2025 saw 14.0% growth driven by the ramp-up of Pune and Indore hospitals.

Geographic Revenue Split

84% of revenue was derived from hospitals in Thane and Pune (Maharashtra) in H1 FY2025, indicating high regional concentration.

Profitability Margins

Operating Profit Margin (OPM) improved to 23.5% in FY2025 from 22.3% in FY2024. PAT margin was 15.3% in FY2025 compared to 16.5% in FY2024.

EBITDA Margin

OPBDIT/OI was 23.5% in FY2025, a 120 bps improvement from 22.3% in FY2024, driven by higher occupancy rates and healthy ARPOB growth.

Capital Expenditure

Planned capital outlay of INR 1,100-1,200 Cr over FY2025-FY2027. Specifically, INR 130-150 Cr in FY2025, INR 400 Cr in FY2026, and INR 450 Cr in FY2027 for greenfield facilities.

Credit Rating & Borrowing

Rated [ICRA]A+ (Positive) for long-term and [ICRA]A1+ for short-term. The company is currently debt-free (except lease liabilities) after repaying all debt in FY2024 via IPO proceeds.

⚙️ Operational Drivers

Capacity Expansion

Current operational capacity of 1,061 beds; planned expansion to approximately 2,500 beds by FY2027 through greenfield projects in Dombivli, Pune, and Mira Road.

Manufacturing Efficiency

Indore hospital became OPBIDTA positive in FY2024 within three years of commencement; efficiency is driven by improving occupancy and ARPOB.

Logistics & Distribution

Distribution is achieved through the physical hospital network in Thane, Pune, and Indore, with upcoming units in Dombivli and Mira Road.

📈 Strategic Growth

Expected Growth Rate

18-20%

Growth Strategy

Doubling bed capacity from 1,061 to 2,500 through three greenfield facilities in Dombivli, Pune, and Mira Road. Strategy focuses on an 'all-hub-no-spoke' model to provide full-service tertiary care.

Products & Services

Multi-specialty tertiary healthcare services (cardiology, oncology, etc.), diagnostic services, and hospitality services (22-room hotel and convention center in Thane).

Brand Portfolio

Jupiter Hospital, Fortune Park (managed by ITC Ltd).

New Products/Services

New greenfield hospitals in Dombivli, Pune, and Mira Road are expected to contribute significantly to the planned capacity increase to 2,500 beds.

Market Expansion

Expansion within Maharashtra (Dombivli, Pune, Mira Road) to solidify its leading position in the Western region.

Market Share & Ranking

Leading player in the Thane region with a current bed capacity of over 1,000.

Strategic Alliances

Management of hotel operations by Fortune Park Hotels (wholly owned by ITC Ltd).

🌍 External Factors

Industry Trends

The healthcare sector is seeing a shift toward organized chains with a current growth rate of ~18-20% for JLHL. Future direction is driven by increasing medical insurance coverage and lifestyle disease prevalence.

Competitive Landscape

Stiff competition from established organized chains and local multi-specialty clinics in the Western region.

Competitive Moat

Durable advantage through an established brand in the Western region and an 'all-hub-no-spoke' model which ensures high-quality tertiary care. Promoters have 20+ years of experience, creating high switching costs for patients seeking specialized care.

Macro Economic Sensitivity

Highly sensitive to per-capita income growth and medical insurance penetration, which drive affordability for tertiary care.

Consumer Behavior

Shift toward organized healthcare providers due to better infrastructure and specialized service availability.

Geopolitical Risks

Minimal direct impact, though global supply chains for medical technology could be affected by trade barriers.

⚖️ Regulatory & Governance

Industry Regulations

Subject to restrictive pricing regulations on medical procedures and medicines by Central and State governments, and strict environmental compliance for bio-medical waste.

Environmental Compliance

Must comply with bio-medical waste management and environmental laws; specific ESG costs are not disclosed.

Taxation Policy Impact

Effective tax rate is approximately 25% based on H1 FY2026 tax payments of INR 33.8 Cr against PBT of INR 136.0 Cr.

Legal Contingencies

The company has disclosed pending litigations in its financial statements, but the specific aggregate case value in INR is not disclosed in available documents.

⚠️ Risk Analysis

Key Uncertainties

The primary risk is the timely commencement and ramp-up of the Dombivli hospital in FY2027, which could impact overall profitability in the initial years due to high fixed costs.